The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome
Open accessAbstract
OBJECTIVES: One-fifth of Covid-19 patients suffer a severe course of Covid-19 infection; however, the specific causes remain unclear. Mast cells (MCs) are activated by SARS-CoV-2. Although only recently recognized, MC activation syndrome (MCAS), usually due to acquired MC clonality, is a chronic multisystem disorder with inflammatory and allergic themes, and an estimated prevalence of 17%. This paper describes a novel conjecture explaining how MCAS might cause a propensity for severe acute Covid-19 infection and chronic post-Covid-19 illnesses. METHODS: Observations of Covid-19 illness in patients with/without MCAS were compared with extensive clinical experience with MCAS. RESULTS: The prevalence of MCAS is similar to that of severe cases within the Covid-19-infected population. Much of Covid-19's hyperinflammation is concordant with manners of inflammation which MC activation can drive. Drugs with activity against MCs or their mediators have preliminarily been observed to be helpful in Covid-19 patients. None of the authors' treated MCAS patients with Covid-19 suffered severe infection, let alone mortality. CONCLUSIONS: Hyperinflammatory cytokine storms in many severely symptomatic Covid-19 patients may be rooted in an atypical response to SARS-CoV-2 by the dysfunctional MCs of MCAS rather than a normal response by normal MCs. If proven, this theory has significant therapeutic and prognostic implications.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Grasselli, G., Zangrillo, A., Zanella, A., Antonelli, M., Cabrini, L., Castelli, A., Cereda, D., Coluccello, A., Foti, G., Fumagalli, R., et al. (2020) · JAMA · doi:10.1001/jama.2020.5394 · Cited by 5,469 · cited 1×
“Approximately 15–20% of Covid-19-infected patients suffer a severe form of the acute infection (Bulut and Kato, 2020; Rabec et al., 2020; Grasselli et al., 2020) hallmarked by hyperinflammatory cytokine storms causing far more morbidity and mortality than from any direct viral cytotoxicity.”
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China
Shi, S., Qin, M., Shen, B., Cai, Y., Liu, T., Yang, F., Gong, W., Liu, X., Liang, J., Zhao, Q., et al. (2020) · JAMA Cardiology · doi:10.1001/jamacardio.2020.0950 · Cited by 4,349
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Chen, T., Wu, D., Chen, H., Yan, W., Yang, D., Chen, G., Ma, K., Xu, D., Yu, H., Wang, H., et al. (2020) · BMJ · doi:10.1136/bmj.m1091 · Cited by 3,903
Covid-19 in Critically Ill Patients in the Seattle Region — Case Series
Bhatraju, P. K., Ghassemieh, B. J., Nichols, M., Kim, R., Jerome, K. R., Nalla, A. K., Greninger, A. L., Pipavath, S., Wurfel, M. M., Evans, L., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004500 · Cited by 2,583
Wang, Y., Wang, Y., Chen, Y., & Qin, Q. (2020) · Journal of Medical Virology · doi:10.1002/jmv.25748 · Cited by 1,531
Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
Troyer, E. A., Kohn, J. N., & Hong, S. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.04.027 · Cited by 964
Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients
Zhou, Z., Ren, L., Zhang, L., Zhong, J., Xiao, Y., Jia, Z., Guo, L., Yang, J., Wang, C., Jiang, S., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.017 · Cited by 938
Mast Cell: A Multi-Functional Master Cell
Krystel-Whittemore, M., Dileepan, K. N., & Wood, J. G. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00620 · Cited by 890
Mast cell-orchestrated immunity to pathogens
Abraham, S. N., & St. John, A. L. (2010) · Nature Reviews Immunology · doi:10.1038/nri2782 · Cited by 837
Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry
Romero-Sánchez, C. M., Díaz-Maroto, I., Fernández-Díaz, E., Sánchez-Larsen, Á., Layos-Romero, A., García-García, J., González, E., Redondo-Peñas, I., Perona-Moratalla, A. B., Del Valle-Pérez, J. A., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009937 · Cited by 737
Cytokine storms: understanding COVID-19
Mangalmurti, N., & Hunter, C. A. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.017 · Cited by 698
Mast cells as sources of cytokines, chemokines, and growth factors
Mukai, K., Tsai, M., Saito, H., & Galli, S. J. (2018) · Immunological Reviews · doi:10.1111/imr.12634 · Cited by 682
Cytokine storm intervention in the early stages of COVID-19 pneumonia
Sun, X., Wang, T., Cai, D., Hu, Z., Chen, J., Liao, H., Zhi, L., Wei, H., Zhang, Z., Qiu, Y., et al. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.04.002 · Cited by 513
Colunga Biancatelli, R. M. L., Berrill, M., Catravas, J. D., & Marik, P. E. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01451 · Cited by 512
Pulmonary fibrosis secondary to COVID-19: a call to arms?
Spagnolo, P., Balestro, E., Aliberti, S., Cocconcelli, E., Biondini, D., Casa, G. D., Sverzellati, N., & Maher, T. M. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30222-8 · Cited by 481
BULUT, C., & KATO, Y. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-172 · Cited by 321
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
Luo, W., Li, Y.-X., Jiang, L.-J., Chen, Q., Wang, T., & Ye, D.-W. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.06.007 · Cited by 296
COVID-19, Mast Cells, Cytokine Storm, Psychological Stress, and Neuroinflammation
Kempuraj, D., Selvakumar, G. P., Ahmed, M. E., Raikwar, S. P., Thangavel, R., Khan, A., Zaheer, S. A., Iyer, S. S., Burton, C., James, D., et al. (2020) · The Neuroscientist · doi:10.1177/1073858420941476 · Cited by 289
Freedberg, D. E., Conigliaro, J., Wang, T. C., Tracey, K. J., Callahan, M. V., Abrams, J. A., Sobieszczyk, M. E., Markowitz, D. D., Gupta, A., O’Donnell, M. R., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.05.053 · Cited by 257
Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy.
Kritas, S. K. (2020) · JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS · doi:10.23812/20-editorial-kritas · Cited by 237
Gómez-Pastora, J., Weigand, M., Kim, J., Wu, X., Strayer, J., Palmer, A. F., Zborowski, M., Yazer, M., & Chalmers, J. J. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.06.033 · Cited by 235
St. John, A. L., Rathore, A. P. S., Yap, H., Ng, M.-L., Metcalfe, D. D., Vasudevan, S. G., & Abraham, S. N. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1105079108 · Cited by 226
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
Seif, F., Aazami, H., Khoshmirsafa, M., Kamali, M., Mohsenzadegan, M., Pornour, M., & Mansouri, D. (2020) · International Archives of Allergy and Immunology · doi:10.1159/000508247 · Cited by 197
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection
Lechowicz, K., Drożdżal, S., Machaj, F., Rosik, J., Szostak, B., Zegan-Barańska, M., Biernawska, J., Dabrowski, W., Rotter, I., & Kotfis, K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9061917 · Cited by 184
Molderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149
COVID ‐19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin
Theoharides, T. C. (2020) · BioFactors · doi:10.1002/biof.1633 · Cited by 142
The biology of Kit in disease and the application of pharmacogenetics
Akin, C., & Metcalfe, D. D. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2004.04.046 · Cited by 133
Viecca, M., Radovanovic, D., Forleo, G. B., & Santus, P. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104950 · Cited by 131
The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19
Bağca, B. G., & Avcı, Ç. B. (2020) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2020.06.013 · Cited by 126
Diagnosis of mast cell activation syndrome: a global "consensus-2"
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., et al. (2021) · Diagnosis · doi:10.1515/dx-2020-0005 · Cited by 115
Self-citationMeyer, L. K., Verbist, K., Albeituni, S., Scull, B., Bassett, R., Stroh, A. N., Sheppard, H., Allen, C. E., Hermiston, M. L., & Nichols, K. E. (2020) · Blood · doi:10.1182/blood.2020006075 · Cited by 104
Characterization of Mast Cell Activation Syndrome
Afrin, L. B., Self, S., Menk, J., & Lazarchick, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.12.013 · Cited by 101
Self-citationHiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19
Spinelli, F. R., Conti, F., & Gadina, M. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc5367 · Cited by 101
Ruscitti, P., Berardicurti, O., Benedetto, P. D., Cipriani, P., Iagnocco, A., Shoenfeld, Y., & Giacomelli, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01130 · Cited by 101
Fominskiy, E. V., Scandroglio, A. M., Monti, G., Calabró, M. G., Landoni, G., Dell’Acqua, A., Beretta, L., Moizo, E., Ravizza, A., Monaco, F., et al. (2020) · Blood Purification · doi:10.1159/000508657 · Cited by 96
Familial Occurrence of Systemic Mast Cell Activation Disease
Molderings, G. J., Haenisch, B., Bogdanow, M., Fimmers, R., & Nöthen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076241 · Cited by 94
Self-citationAfrin, L. B., Butterfield, J. H., Raithel, M., & Molderings, G. J. (2016) · Annals of Medicine · doi:10.3109/07853890.2016.1161231 · Cited by 74
Self-citationMolderings, G. J., Kolck, U. W., Scheurlen, C., Brüss, M., Homann, J., & Von Kügelgen, I. (2007) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520701245744 · Cited by 73
Self-citationMast Cells in Cardiovascular Disease: From Bench to Bedside
Hermans, M. A. W., van Lennep, J. E. R., van Daele, P. L. A., & Bot, I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20143395 · Cited by 66
Sepay, N., Sepay, N., Hoque, A. A., Mondal, R., Halder, U. C., & Muddassir, M. (2020) · Structural Chemistry · doi:10.1007/s11224-020-01537-5 · Cited by 62
Almerie, M. Q., & Kerrigan, D. D. (2020) · Medical Hypotheses · doi:10.1016/j.mehy.2020.109883 · Cited by 61
Molderings, G. J., Meis, K., Kolck, U. W., Homann, J., & Frieling, T. (2010) · Immunogenetics · doi:10.1007/s00251-010-0474-8 · Cited by 58
Self-citationAfrin, L. B., Pöhlau, D., Raithel, M., Haenisch, B., Dumoulin, F. L., Homann, J., Mauer, U. M., Harzer, S., & Molderings, G. J. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.002 · Cited by 52
Self-citationMast Cell Stabilization Improves Survival by Preventing Apoptosis in Sepsis
Ramos, L., Peña, G., Cai, B., Deitch, E. A., & Ulloa, L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000273 · Cited by 51
The genetic basis of mast cell activation disease - looking through a glass darkly
Molderings, G. J. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2014.09.001 · Cited by 50
Self-citationHaenisch, B., Nöthen, M. M., & Molderings, G. J. (2012) · Immunology · doi:10.1111/j.1365-2567.2012.03627.x · Cited by 48
Self-citationMast cell activation disease and the modern epidemic of chronic inflammatory disease
Afrin, L. B. (2016) · Translational Research · doi:10.1016/j.trsl.2016.01.003 · Cited by 39 · cited 2×
“…chronic multisystem inflammatory illness is increasingly being suspected to be rooted in (initiation of, or more likely escalation of pre-existing) MCAS (e.g. Epstein-Barr virus infection, tick-borne infections) rather than chronic active infection (Afrin, 2016b, Kempuraj et al., 2020).”
Self-citationA concise, practical guide to diagnostic assessment for mast cell activation disease
Afrin, L. B., & Molderings, G. J. (2014) · World Journal of Hematology · doi:10.5315/wjh.v3.i1 · Cited by 37
Self-citationA concise, practical guide to diagnostic assessment for mast cell activation disease
Afrin, L. B., & Molderings, G. J. (2014) · World Journal of Hepatology · doi:10.5315/wjh.v3.i1.1 · Cited by 33
Self-citationValent, P., Akin, C., Bonadonna, P., Brockow, K., Niedoszytko, M., Nedoszytko, B., Butterfield, J. H., Álvarez‐Twöse, I., Sotlar, K., Schwaab, J., et al. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.06.009 · Cited by 33
Repositioning Chromones for Early Anti-inflammatory Treatment of COVID-19
Sestili, P., & Stocchi, V. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00854 · Cited by 28
Rabec, C. A., Gonzalez‐Bermejo, J., Mercy, M., Grassion, L., Pontier, S., Patout, M., Luque, R. C., Delafosse, C., Rahérison, C., Maître, B., et al. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100768 · Cited by 26
Criado, P. R., Pagliari, C., Criado, R. F. J., Marques, G. F., & Belda, W. (2020) · Dermatologic Therapy · doi:10.1111/dth.14068 · Cited by 25
Molderings, G. J. (2016) · Translational research · doi:10.1016/j.trsl.2016.01.001 · Cited by 23
Self-citationHaenisch, B., Fröhlich, H., Herms, S., & Molderings, G. J. (2014) · Immunogenetics · doi:10.1007/s00251-014-0768-3 · Cited by 19
Self-citationKılınç, E., & Kılınç, Y. B. (2020) · Anadolu Kliniği Tıp Bilimleri Dergisi · doi:10.21673/anadoluklin.720116 · Cited by 18
Scala, S., & Pacelli, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01201 · Cited by 18
Altmüller, J., Haenisch, B., Kawalia, A., Menzen, M., Nöthen, M. M., Fier, H., & Molderings, G. J. (2017) · Immunogenetics · doi:10.1007/s00251-017-0981-y · Cited by 14
Self-citation
Cited by
Characterizing long COVID in an international cohort: 7 months of symptoms and their impact
Davis, H. E., Assaf, G. S., McCorkell, L., Wei, H., Low, R. J., Re'em, Y., Redfield, S., Austin, J. P., & Akrami, A. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.101019 · Cited by 2,881
“tical dashed lines indicate the range for “No fatigue”[10-21], “Fatigue”[22-34], and “Extreme” (>=35).”
Long COVID or post-COVID-19 syndrome: putative pathophysiology, risk factors, and treatments
Yong, S. J. (2021) · Infectious Diseases · doi:10.1080/23744235.2021.1924397 · Cited by 1,339
Pathophysiology and mechanism of long COVID: a comprehensive review
Castanares-Zapatero, D., Chalon, P., Kohn, L., Dauvrin, M., Detollenaere, J., Maertens de Noordhout, C., Primus-de Jong, C., Cleemput, I., & Van den Heede, K. (2022) · Annals of Medicine · doi:10.1080/07853890.2022.2076901 · Cited by 585
Fernández-de-las-Peñas, C., Palacios-Ceña, D., Gómez-Mayordomo, V., Florencio, L. L., Cuadrado, M. L., Plaza-Manzano, G., & Navarro-Santana, M. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.06.009 · Cited by 574
Pretorius, E., Vlok, M., Venter, C., Bezuidenhout, J. A., Laubscher, G. J., Steenkamp, J., & Kell, D. B. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01359-7 · Cited by 518
Metadata
- Authors
- Afrin, L. B., Weinstock, L. B., & Molderings, G. J.
- Venue
- International Journal of Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2020-11
- Volume
- 100
- Pages
- 327-332
- ISSN
- 1201-9712 (ISSN-L)
- OpenAlex
- W3086293749
- Cited by
- 314
- References
- 63
- FWCI
- 16.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.